PRWCX vs VUG: 29% overlap
T. Rowe Price Capital Appreciation and Vanguard Growth ETF share 28.9% of their portfolios by weight — computed as Σ min(wA, wB) over every holding both funds own.
Different holding dates. These holdings were published about 3 months apart — PRWCX as of 2026-03-31, the rest through 2026-06-30. Each fund is compared using its most recent file, so any trading in between shows up as a difference.
You would hold two tickers and get the diversification of 1.7. Two funds that shared nothing would score 2.0; two identical funds score 1.0.
Top shared holdings
PRWCX and VUG hold 22 of the same securities. The ten contributing most to the overlap figure:
| Holding | in PRWCX | in VUG | Δ |
|---|---|---|---|
| AMZN | 4.8% | 4.5% | 0.3% |
| MSFT | 4.2% | 7.6% | 3.3% |
| AAPL | 3.6% | 11.6% | 8.1% |
| META | 3.7% | 3.4% | 0.3% |
| NVDA | 3.0% | 12.6% | 9.6% |
| GOOGL | 2.3% | 5.7% | 3.5% |
| AVGO | 1.8% | 4.3% | 2.5% |
| AMD | 1.4% | 2.6% | 1.3% |
| MA | 0.9% | 1.1% | 0.2% |
| LLY | 0.8% | 2.8% | 2.0% |
Where PRWCX and VUG differ
Sector weights as a share of each fund, ordered by the size of the gap rather than the size of the sector — two funds that overlap heavily still usually diverge somewhere.
| Sector | PRWCX | VUG | Δ |
|---|---|---|---|
| Information Technology | 17.8% | 56.0% | −38.2pp |
| Unclassified | 20.3% | 0.1% | +20.1pp |
| Treasuries | 18.2% | 0.0% | +18.2pp |
| Communication Services | 6.7% | 15.3% | −8.6pp |
| Health Care | 12.2% | 4.7% | +7.5pp |
| Utilities | 7.1% | 0.0% | +7.1pp |
| Cash & Other | 5.0% | 0.0% | +5.0pp |
| Consumer Discretionary | 7.2% | 11.4% | −4.3pp |
Δ is PRWCX minus VUG, in percentage points. Sector data is not published by every issuer, so “Unclassified” is a real category rather than a gap in the table.
What each fund holds alone
61.4% of PRWCX by weight, held in no part of VUG.
38.0% of VUG by weight, held in no part of PRWCX.
A large count with a small weight is the usual shape: the positions one fund adds are typically its smallest ones.
Concentration and cost
| PRWCX | VUG | |
|---|---|---|
| Top 10 holdings | 46.0% | 60.3% |
| Positions held | 151 | 147 |
| Cost per $10,000 held, per year | $72 | $3 |
Cost is the expense ratio applied to $10,000; it excludes any brokerage commission, bid-ask spread or tax consequence. Figures are facts about the funds, not a suggestion about which to hold.
Frequently asked
How much do PRWCX and VUG overlap?
PRWCX and VUG overlap 28.9% by portfolio weight — moderate overlap. They share 22 holdings. The figure comes from current issuer holdings files (PRWCX as of 2026-03-31, VUG as of 2026-06-30).
How is the overlap between PRWCX and VUG calculated?
As the sum of the smaller weight in each fund, over every holding both funds own: Σ min(wA, wB). If PRWCX holds a stock at 6% and VUG holds the same stock at 4%, 4% counts as shared. The result is bounded between 0% and 100%, and it is computed after looking through any fund-of-funds to the underlying holdings.
Is it redundant to hold both PRWCX and VUG?
That depends on your goals — we state facts, not advice. At 28.9% overlap, each fund still contributes meaningfully distinct exposure.
What does PRWCX own that VUG doesn't?
PRWCX holds 151 positions and VUG holds 147; 128 of PRWCX's positions don't appear in VUG at all, and they are 61.4% of PRWCX by weight.
You probably hold more than two funds
This page compares PRWCX and VUG. Paste your whole portfolio — brokerage, 401(k), IRA — and see the overlap across every fund at once, plus what you actually own underneath them and your own Effective Funds number. Free, no account, nothing stored.
X-ray my portfolio — free →Watch PRWCX vs VUG
We re-read both funds’ published holdings every weeknight. Leave an address and we'll tell you when what's inside actually changes.
Not sending yet — email alerts are built but switched off, and you'll be among the first when they turn on. No spam, one-click unsubscribe.
Related comparisons
Sources: issuer holdings files, PRWCX as of 2026-03-31, VUG as of 2026-06-30. Weights are fractions of each fund. Diagnostics, not advice.